Macrophages acquire specialized phenotypes in response to signals from the local microenvironment, hence polarizing toward a specific activation state. 5 The tumor microenvironment has been shown to skew TAMs toward a wound healing/ regulatory state that resembles several aspects of the alternatively-activated macrophage phenotype. 6 We have recently shown that c-MYC is induced in human macrophages during alternative activation in vitro and controls the expression of several alternative activation-specific markers, 4 suggesting that targeting c-MYC function in TAMs may limit tumor growth. + macrophages in the spleen, thymus and lymph nodes.
To investigate oncogenesis in mice with a macrophage-specific deletion of c-Myc, we injected B16-F10 melanoma cells carrying the firefly luciferase gene into the flanks of Mθ-c-Myc-KO and control c-Myc fl/fl mice and performed in vivo luciferase bioluminescent assays to assess tumor growth over time. These longitudinal studies together with post-mortem analysis (performed 15 d after tumor-cell inoculation) revealed a reduced tumor growth in Mθ-c-Myc-KO mice. 7 The analysis of neoplastic lesions developing in Mθ-c-Myc-KO mice showed a reduced expression of c-Myc in TAMs but no effect on their proliferative or apoptotic response, which, as in control animals, were very low. Interestingly, a detailed transcription factors of the MYC family regulate several homeostatic cell functions, and their role as proto-oncogenes has been the focus of interest for decades. we have recently demonstrated that c-MYC is expressed by tumor-associated macrophages (tAMs) and regulates their phenotype and pro-tumor activities in vivo.
Mθ-c-Myc-KO bone marrow-derived macrophages exposed to tumor-conditioned medium in vitro exhibited lower expression levels of VEGF, MMP9 and HIF1α than c-Myc-proficient macrophages, and this was accompanied by a decreased protumor activity, as revealed by reduced MMP activity in zymogram assays, by inhibition of endothelial cell proliferation and migration in wound healing assays, as well as by inhibition of CD8 + T lymphocyte proliferation.
Our work identified c-MYC as an important regulator of TAM biology and maturation in vivo (Fig. 1) . Compared with control animals, Mθ-c-Myc-KO mice, which specifically lack c-Myc in myeloid cells, exhibit defective tumor angiogenesis and reduced melanoma and fibrosarcoma development in xenographt models. These findings point to c-MYC important drivers of cancer-related inflammation. 10 It would therefore be interesting to analyze whether c-MYC and NFκB act in parallel or sequentially, and if they are expressed in the same macrophages or in distinct macrophage populations exhibiting distinct intratumoral distributions.
TAMs isolated from Mθ-c-Myc-KO mice also showed an attenuation of protumor functions (such as a reduced expression of vascular endothelial growth factor, VEGF, matrix metalloproteinase 9, MMP9 and hypoxia-inducible factor 1α, HIF1α), and this was associated with impaired tissue remodeling and angiogenesis in vivo (as assessed by molecular fluorescence tomography) as well as with a reduced development of new blood vessels (as revealed by the postmortem confocal microscopy analysis of tumors). 7 Consistent with these findings, inactivation as an attractive strategy for cancer treatment. We believe that the new Mθ-c-Myc-KO mouse model will also be useful for analyzing the role of c-MYC in other inflammatory diseases associated with myeloid cell infiltration.
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